IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,680 | +10.6% | 500 | 0.0% | 0.01% | +14.3% |
| Q2 2023 | $20,515 | +14.8% | 500 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $17,870 | -5.4% | 500 | 0.0% | 0.01% | -12.5% |
| Q4 2022 | $18,885 | -57.1% | 500 | -49.8% | 0.01% | -52.9% |
| Q3 2022 | $44,000 | +18.9% | 997 | 0.0% | 0.02% | +13.3% |
| Q2 2022 | $37,000 | 0.0% | 997 | 0.0% | 0.02% | +36.4% |
| Q1 2022 | $37,000 | +23.3% | 997 | 0.0% | 0.01% | +37.5% |
| Q4 2021 | $30,000 | -9.1% | 997 | 0.0% | 0.01% | -20.0% |
| Q3 2021 | $33,000 | -17.5% | 997 | -0.3% | 0.01% | -9.1% |
| Q2 2021 | $40,000 | -11.1% | 1,000 | 0.0% | 0.01% | -21.4% |
| Q1 2021 | $45,000 | -21.1% | 1,000 | 0.0% | 0.01% | -22.2% |
| Q4 2020 | $57,000 | -65.7% | 1,000 | -81.5% | 0.02% | -74.3% |
| Q3 2020 | $166,000 | +186.2% | 5,400 | +440.0% | 0.07% | +191.7% |
| Q2 2020 | $58,000 | +23.4% | 1,000 | 0.0% | 0.02% | -20.0% |
| Q1 2020 | $47,000 | -21.7% | 1,000 | 0.0% | 0.03% | +25.0% |
| Q4 2019 | $60,000 | +1.7% | 1,000 | 0.0% | 0.02% | -20.0% |
| Q3 2019 | $59,000 | -7.8% | 1,000 | 0.0% | 0.03% | -16.7% |
| Q2 2019 | $64,000 | -21.0% | 1,000 | 0.0% | 0.04% | -34.5% |
| Q1 2019 | $81,000 | +50.0% | 1,000 | 0.0% | 0.06% | +41.0% |
| Q4 2018 | $54,000 | +5.9% | 1,000 | 0.0% | 0.04% | +56.0% |
| Q3 2018 | $51,000 | +21.4% | 1,000 | 0.0% | 0.02% | +38.9% |
| Q2 2018 | $42,000 | -4.5% | 1,000 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $44,000 | -12.0% | 1,000 | 0.0% | 0.02% | -10.0% |
| Q4 2017 | $50,000 | -2.0% | 1,000 | 0.0% | 0.02% | -13.0% |
| Q3 2017 | $51,000 | 0.0% | 1,000 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $51,000 | +27.5% | 1,000 | 0.0% | 0.02% | +15.0% |
| Q1 2017 | $40,000 | -16.7% | 1,000 | 0.0% | 0.02% | -16.7% |
| Q4 2016 | $48,000 | +29.7% | 1,000 | 0.0% | 0.02% | +26.3% |
| Q3 2016 | $37,000 | +60.9% | 1,000 | 0.0% | 0.02% | +58.3% |
| Q2 2016 | $23,000 | -43.9% | 1,000 | 0.0% | 0.01% | -58.6% |
| Q1 2016 | $41,000 | -33.9% | 1,000 | 0.0% | 0.03% | -6.5% |
| Q4 2015 | $62,000 | – | 1,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |